Tumor suppression by small molecule inhibitorss of translation initiation

Oncotarget

Volumn 3, Issue 8, 2012, Pages 869-881

  Chen, Limo ^a   Aktas, Bertal H ^a,b   Wang, Yibo ^a   He, Xiaoying ^a,c   Sahoo, Rupam ^a   Zhang, Nancy ^a   Denoyelle, Severine ^a   Kabha, Eihab ^a   Yang, Hongwei ^a   Freedman, Revital Yefidoff ^a   Supko, Jeffrey G ^a,c   Chorev, Michael ^a,b   Wagner, Gerhard ^a   Halperin, Jose A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

EIF2; EIF4e; EIF4F; Ternary complex; Translation

Indexed keywords

4EGI 1; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BETA ACTIN; COMPOUND 1181; CYCLIN D1; CYCLIN E; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4E; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MYC PROTEIN; PROTEIN BCL 2; SMALL MOLECULE TRANSLATION INITIATION INHIBITOR; SURVIVIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSLATION INITIATION;

EID: 84868622977     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.598     Document Type: Article

References (49)

1. Shahbazian D, Parsyan A, Petroulakis E, Hershey J and Sonenberg N. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle. 2010; 9(20):4106-4109.
2. Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A and Biffo S. Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer cell. 2011; 19(6):765-775.
3. Brina D, Grosso S, Miluzio A and Biffo S. Translational control by 80S formation and 60S availability: the central role of eIF6, a rate limiting factor in cell cycle progression and tumorigenesis. Cell Cycle. 2011; 10(20):3441-3446.
4. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol. 1991; 115(4):887-903.
5. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N and Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol. 1993; 13(12):7358-7363.
6. Dua K, Williams TM and Beretta L. Translational control of the proteome: relevance to cancer. Proteomics. 2001; 1(10):1191-1199.
7. Gingras AC, Raught B and Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem. 1999; 68:913- 963.
8. Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, Nawas S, McDonald JC and DeBenedetti A. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg. 2002; 235(5):732-738; discussion 738-739.
9. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB and Polunovsky VA. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer cell. 2004; 5(6):553-563.
10. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW and Sonenberg N. eIF4E--from translation to transformation. Oncogene. 2004; 23(18):3172-3179.
11. Donze O, Jagus R, Koromilas AE, Hershey JW and Sonenberg N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. Embo J. 1995; 14(15):3828-3834.
12. Jiang H, Coleman J, Miskimins R and Miskimins WK. Expression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int. 2003; 3(1):2.
13. Graff JR, Boghaert ER, De Benedetti A, Tudor DL, Zimmer CC, Chan SK and Zimmer SG. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer. 1995; 60(2):255-263.
14. Panwalkar A, Verstovsek S and Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004; 100(4):657-666.
15. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A and Harris AL. Eukaryotic initiation factor- 4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer. 2000; 82(1):161-166.
16. Rosenwald IB, Hutzler MJ, Wang S, Savas L and Fraire AE. Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer. 2001; 92(8):2164-2171.
17. De Benedetti A and Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol. 1999; 31(1):59-72.
18. Nathan CA, Amirghahri N, Rice C, Abreo FW, Shi R and Stucker FJ. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope. 2002; 112(12):2129-2140.
19. Berkel HJ, Turbat-Herrera EA, Shi R and de Benedetti A. Expression of the translation initiation factor eIF4E in the polyp- cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev. 2001; 10(6):663-666.
20. Pincheira R, Chen Q, Huang Z and Zhang JT. Two subcellular localizations of eIF3 p170 and its interaction with membrane-bound microfilaments: implications for alternative functions of p170. Eur J Cell Biol. 2001; 80(6):410-418.
21. Eberle J, Krasagakis K and Orfanos CE. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer. 1997; 71(3):396-401.
22. Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T, Horiuchi S, Shichita M, Yamamoto N and Yamamoto M. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res. 2000; 20(4):2489-2494.
23. Haydon MS, Googe JD, Sorrells DS, Ghali GE and Li BD. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer. 2000; 88(12):2803-2810.
24. Wang S, Lloyd RV, Hutzler MJ, Rosenwald IB, Safran MS, Patwardhan NA and Khan A. Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma. Thyroid. 2001; 11(12):1101-1107.
25. Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L, Chen JJ and Woda BA. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non- Hodgkin's lymphomas. Am J Pathol. 1999; 155(1):247-255.
26. Raught B, Gingras A-C, James A, Medina D, Sonenberg N and Rosen JM. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein β isoform and up-regulation of the eukaryotic translation initiation factor 2α are correlated with neoplastic transformation of Mammary epithelial cells. Cancer Res. 1996; 56:4382-4386.
27. De Benedetti A and Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004; 23(18):3189-3199.
28. Marshall L, Kenneth NS and White RJ. Elevated tRNA(iMet) synthesis can drive cell proliferation and oncogenic transformation. Cell. 2008; 133(1):78-89.
29. Aktas H, Fluckiger R, Acosta JA, Savage JM, Palakurthi SS and Halperin JA. Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc Natl Acad Sci U S A. 1998; 95(14):8280- 8285.
30. Palakurthi SS, Fluckiger R, Aktas H, Changolkar AK, Shahsafaei A, Harneit S, Kilic E and Halperin JA. Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res. 2000; 60(11):2919-2925.
31. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM and Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 2001; 61(16):6213-6218.
32. Brunn GJ, Hudson CC, Sekulic W, J.M., Hosoi H, Houghton PJ, Lawrence JC, Jr. and Abraham RT. Phosphorylation of the translational repressor PHAS-1 by the mammalian target of rapamycin. Science. 1997; 277:99-101.
33. Beretta L, Gingras AC, Svitkin YV, Hall MN and Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap- dependent initiation of translation. Embo J. 1996; 15(3):658-664.
34. Mita MM, Mita A and Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther. 2003; 2(4 Suppl 1):S169-177.
35. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 2007; 117(9):2638-2648.
36. Malina A, Cencic R and Pelletier J. Targeting translation dependence in cancer. Oncotarget. 2011; 2(1-2):76-88.
37. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, Porco JA, Jr. and Pelletier J. Antitumor activity and mechanism of action of the cyclopenta[b] benzofuran, silvestrol. PLoS One. 2009; 4(4):e5223.
38. Bordeleau ME, Cencic R, Lindqvist L, Oberer M, Northcote P, Wagner G and Pelletier J. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem Biol. 2006; 13(12):1287-1295.
39. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA and Wagner G. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 2007; 128(2):257-267.
40. Natarajan A, Fan YH, Chen H, Guo Y, Iyasere J, Harbinski F, Christ WJ, Aktas H and Halperin JA. 3,3-diaryl-1,3- dihydroindol-2-ones as antiproliferatives mediated by translation initiation inhibition. J Med Chem. 2004; 47(8):1882-1885.
41. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des. 16(1):34-44.
42. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-64.
43. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM and Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002; 297(5578):102-104.
44. Wysocki PJ. Targeted therapy of hepatocellular cancer. Expert Opin Investig Drugs. 19(2):265-274.
45. Zitzmann K, Ruden J, Brand S, Goke B, Lichtl J, Spottl G and Auernhammer CJ. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett. 2010; 295(1):100-109.
46. Yu Y, Marintchev A, Kolupaeva VG, Unbehaun A, Veryasova T, Lai SC, Hong P, Wagner G, Hellen CU and Pestova TV. Position of eukaryotic translation initiation factor eIF1A on the 40S ribosomal subunit mapped by directed hydroxyl radical probing. Nucleic Acids Res. 2009; 37(15):5167-5182.
47. Gelev V, Aktas H, Marintchev A, Ito T, Frueh D, Hemond M, Rovnyak D, Debus M, Hyberts S, Usheva A, Halperin J and Wagner G. Mapping of the auto-inhibitory interactions of protein kinase R by nuclear magnetic resonance. J Mol Biol. 2006; 364(3):352-363.
48. Chen T, Ozel D, Qiao Y, Harbinski F, Chen L, Denoyelle S, He X, Zvereva N, Supko JG, Chorev M, Halperin JA and Aktas BH. Chemical genetics identify eIF2alpha kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol. 2011; 7(9):610-616.
49. Ziegeler G, Ming J, Koseki JC, Sevinc S, Chen T, Ergun S, Qin X and Aktas BH. Embryonic lethal abnormal vision-like HuR-dependent mRNA stability regulates post-transcriptional expression of cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem. 2010; 285(20):15408- 15419.